What Syntar Treats: Main Uses and Benefits

Syntar (Dextran 70 / Hypromellose) is commonly used for managing symptoms related to temporary or persistent Ocular Dryness. This preparation is considered relevant in contexts marked by increased discomfort or tension and is applied across therapeutic domains where additional symptomatic support is needed.

The preparation is relevant for managing conditions involving episodic or fluctuating manifestations of dryness, such as xerophthalmia. It may assist with managing symptom clusters that may become intense or disruptive, including burning, stinging, and grittiness.

“The preparation is applicable within clinical settings that involve acute or disruptive symptom patterns, offering support during difficult episodes.”

Syntar is commonly used when symptoms are triggered by external factors like wind and dry air, or when symptoms become more disruptive during digital device use. It is commonly employed by contact lens wearers and individuals managing symptoms within the mild to moderate severity range. This may support the patient during difficult episodes by easing distress and can assist with managing symptoms that interfere with routine activities.

Quick Fact: Relief for Dry Eye Discomfort
Symptom Domain	Symptoms related to physical discomfort, foreign body sensation, and dryness.
Usage Context	Often used during phases when symptoms become more noticeable, such as during computer use or in dry environments.
Key Benefit	Supports the patient by easing distress and contributing to general well-being during symptomatic phases.

Regulatory References

1. NIH DailyMed Label

The eligibility for using Syntar, an Ophthalmic Agent classified as an Eye Lubricant, is defined by regulatory documents based on patient sensitivity and local ocular conditions, with negligible systemic restrictions.

Category	Official Regulatory Statement
Populations for whom use is contraindicated	The product is contraindicated in patients with known hypersensitivity to Dextran 70, Hypromellose, or any other inactive component (excipients).
Age-related eligibility rules	Use is suitable for Adults and the Elderly. The label advises consulting a health professional before use in children under 6 years of age.
Pregnancy and lactation eligibility status	Due to negligible systemic exposure, use is generally considered acceptable during both pregnancy and breastfeeding. Some regulatory labeling advises asking a health professional before use.
Eligibility-related restrictions	Patients must discontinue use if the solution changes color or becomes cloudy. Discontinuation is also required if severe symptoms, such as eye pain, vision changes, or persistent redness/irritation, develop or worsen after 72 hours.

Regulatory documents define eligibility primarily through a single absolute contraindication (hypersensitivity). All other eligibility rules are conditional restrictions that govern appropriate use based on ocular status and product integrity, consistent with the product's non-systemic classification.

Interactions with other medicines and products

Syntar (Dextran 70 / Hypromellose) is an ophthalmic lubricant, and its official interaction profile is defined by its topical route of administration and lack of systemic absorption. Due to these characteristics, government regulatory documents confirm that no systemic pharmacokinetic or pharmacodynamic interactions with other medicines, food, alcohol, or supplements are documented or expected.

Administration-Timing Interaction

The only official restriction concerns the local physical interaction between Syntar and other medicines applied to the eye.

Interaction Scope	Official Regulatory Information
Interacting Product Category	Other locally acting ophthalmic medicinal products (eye drops or eye ointments).
Mechanistic Basis	Local physical interference with the administration or retention of a co-administered product.
Timing Restriction	Co-administration with another topical ophthalmic product must be separated by a minimum of 5 minutes to prevent dilution or washout.
Procedural Constraint	Eye ointments are specifically designated to be administered last following the application of any liquid eye drops.

This constraint is mandatory and is classified as an administration-timing rule, not a drug–drug interaction that alters systemic drug exposure. The regulatory profile is consistently defined by the absence of systemic interaction concerns across all populations.

Syntar interacts with specific molecular targets to modulate signaling pathways within targeted biological systems. This mechanism results in altered output within affected signaling cascades.

---

Receptor-Mediated Signaling Modulation

Syntar acts within domains involving key receptor-mediated signaling cascades, selectively engaging mechanisms that influence the initial, rapid molecular steps. This modulation influences the output of early molecular signals within the cascade.

---

Regulation of Dysregulated Physiological Processes

The drug initiates or suppresses signaling sequences to modulate overactive or dysregulated processes that may escalate under certain conditions. By affecting systems where specific transmitters or mediators dominate, Syntar modifies the activity of processes driven by distinct signaling patterns.

---

Modulation of Systemic Physiological Responses

Syntar's activity leads to the modulation of heightened physiological responses at a systemic level. This pathway adjustment alters the magnitude of mediator activity, which results in measurable alterations in physiological response.

How to Use Syntar: Official Administration Guidelines

The administration of Syntar (Dextran 70 / Hypromellose Ophthalmic Solution) follows standard usage principles for over-the-counter ophthalmic lubricants. This preparation is strictly for Topical Ophthalmic administration and is not intended for injection or ingestion.

---

Official Dosing and Frequency

Usage is characterized by a flexible, as-needed (PRN) schedule, allowing for application when symptoms of minor ocular irritation recur. The standard regimen involves the instillation of one (1) or two (2) drops into the affected eye(s) per application. Due to the topical nature of the product, its use is independent of meal timing.

---

Procedural Administration Constraints

Specific procedural steps are necessary for proper use and maintenance of sterility:

• Contamination Prevention: Users must take care to ensure the dropper tip does not come into contact with the eye, fingers, or any other surface during the instillation process.
• Contact Lens Removal: Contact lenses must be removed prior to application, particularly when using formulations that contain a preservative.
• Concurrent Use: If other eye drop medications are being used, a time interval, typically 5 to 10 minutes, should be observed between the application of Syntar and the other product to prevent wash-out.

---

Population and Duration Rules

No explicit dose adjustments are defined for older adults or individuals with renal or hepatic impairment, as the drug's action is localized to the eye surface. The same dosage of 1 or 2 drops as needed is generally applied for use in adults and children aged six years and older. The product is intended for short-term, temporary relief. A critical constraint on self-treatment is identified: use must be discontinued and a healthcare professional consulted if eye symptoms such as pain, vision changes, or irritation persist or worsen for more than 72 hours.

Research Evidence / Overview of Studies for Syntar

---

Evidence for Managing Temporary and Persistent Ocular Dryness

Research exploring ophthalmic lubricants like Syntar often involves short-term Randomized Controlled Trials (RCTs) and various observational studies. These studies are used in research exploring how symptoms change over time and typically include adults experiencing mild to moderate dryness. The primary focus of these trials is to explore how symptoms related to physical discomfort are measured, such as burning, stinging, and grittiness, which are common complaints in temporary or episodic ocular dryness.

The studies report how symptoms evolved in the observed populations during the research period. Research describes changes measured in patient-reported outcomes describing perceived discomfort. For instance, some trials reported patterns observed in the measurements of patient comfort during the study period.

---

Outcomes Studied Beyond Symptom Relief

Studies related to this product have explored more than just patient comfort. Researchers have also applied in studies examining physical metrics of the eye's tear film. The research explored outcomes related to physical discomfort by evaluating the stability of the protective tear layer on the eye's surface.

For example, studies have examined the Tear Break-Up Time (TBUT), which is a method of measuring how quickly the tear film begins to break down after a blink. Measurements of the physical characteristics of the tear film were observed in some studies following the application of the polymer combination. This research contributes to understanding short-term measurements of the solution's properties on the eye's surface, but evidence remains limited concerning long-term structural changes to the eye itself.

---

What Remains Uncertain and Research Gaps

Studies for ophthalmic lubricants primarily focus on short-term observation, with follow-up durations often limited to a few days up to 4 weeks to capture immediate changes. Because the trials are generally short, long-term outcomes are not well characterized. Research provides context but not individual predictions about the duration of measured outcomes over months or years.

The evidence quality varies across studies. Comparative evidence is lacking for a direct, long-term comparison of Syntar against every other available artificial tear formulation. Data for certain groups, such as children, remain insufficient, and the research focus on symptomatic measurements means that long-term outcomes are not well characterized across the entire evidence landscape.

Key Studies & References

1. Comparison of the clinical efficacy of preserved and preservative-free hydroxypropyl methylcellulose-dextran-containing eyedrops
2. Label: WALGREENS ARTIFICAL TEARS FREE- dextran 70, hypromellose solution/ drops (FDA/DailyMed)
3. Short-Term Changes in Tear Film Stability and Tear Volume Following the Application of Various DED Management Options in a Healthy Young Population

Common questions about Syntar (FAQ)

---

Q: How is Syntar thought to work inside the eye?

Syntar is classified as a topical ophthalmic agent and is intended to relieve symptoms of dryness, burning, and irritation. Official product information states that the active ingredients, Dextran 70 and Hypromellose, function to supplement and stabilize the tear film, enhancing corneal wetting and promoting tear film stability on the eye's surface.

---

Q: What should I do if the medicine becomes cloudy?

Regulatory information indicates that Syntar is contraindicated and should not be used if the solution changes color or becomes cloudy, as this may be a sign of contamination. If this change is noticed, the official label advises that the product should no longer be used. Furthermore, if symptoms such as irritation or redness are present and persist or worsen for more than 72 hours, official guidance is to discontinue use and consult a health professional.

---

Q: What is the typical dose of Syntar for a child?

Official directions for use state that the product is generally approved for use in adults and children aged six years and older for temporary relief. For children under 6 years of age, official documentation requires consultation with a health professional before use.

Official Storage and Disposal Requirements

Syntar (Dextran 70 / Hypromellose Ophthalmic Solution) must be stored strictly according to the conditions defined in the official product labeling to maintain its quality and sterility.

Storage Constraint	Requirement
Temperature	Store at Controlled Room Temperature (not above 25°C). Do not refrigerate or freeze.
Stability	Discard any unused contents 4 weeks after first opening. Do not use past the expiration date.
Container	Keep the container tightly closed after use; do not touch the tip to any surface. Do not use if the solution appears cloudy or changes color.
Protection	Always store the medicine out of the sight and reach of children.

For disposal, unused or expired Syntar should be taken to a drug take-back program or disposed of in the household trash by following the official guidance of mixing it with an undesirable substance, such as dirt or used coffee grounds, before sealing and discarding. The product should not be disposed of by flushing it down the toilet.